Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Aug 17;82(3):428–437. doi: 10.1124/mol.112.077966

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

U.S. Government work not protected by U.S. copyright

PMC Copyright notice

Fig. 2. — A and B, voltage protocol and resulting currents elicited from CHO cells expressing Kv11.1-HA-WT or KV11.1-HA-S890A (black trace), Kv11.1-HA-WT or Kv11.1-HA-S890A in cells treated for 2 h with PMA (red trace), and Kv11.1-HA-WT or KV11.1-HA-S890A in cells pretreated for 2 h with PKC 20-28 and for 2 h with PMA (blue trace). Ensemble averages of eight traces of Kv11.1-HA-WT, Kv11.1-HA-WT + PMA, or KV11.1-HA-S890A mutant channel are represented. To confirm that the electrical activities were specifically recorded from the Kv11.1 channel, currents were isolated by application of the Kv11.1 selective class III antiarrhythmic agent N-(2-{1-[2-(6-methyl-pyridin-2-yl)-ethyl]-piperidine-4-carbonyl}-phenyl)-methanesulfonamide (E4031), which completely blocks Kv11.1 ion channel currents at micromolar (5–10 μM) concentrations (green traces). C, amplitude histograms of the basal peak current activity recorded from CHO cells 12 to 18 h after transfection with Kv11.1-HA-WT (n = 8) or Kv11.1-HA-S890A (n = 8) channels in CHO cells pharmacologically treated as indicated. Data are means ± S.E. *, P < 0.05.